peginterferon beta-1a vs Rebif (interferon beta 1a)
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Multiple Sclerosis
Shared mechanisms: Interferon beta receptor (type I IFN signaling) · Type I interferon receptor · full Multiple Sclerosis pipeline
peginterferon beta-1a · Plegridy
Marketed by Biogen
NCT00906399 · Phase 3 · completed
This was a large, randomized, triple-blind, placebo-controlled trial with 1,516 participants. Its primary clinical endpoint, annualized relapse rate at one year, was statistically significantly lower with both peginterferon beta-1a schedules than with placebo (p=0.0007 for every 2 weeks and p=0.0114 for every 4 weeks).
Next expected readout: May 2027 · NCT03958877 (registry estimate)
Reported efficacy
Annualized Relapse Rate (ARR) at 1 Year: Annualized Relapse Rate (ARR) at 1 Year (1 Year): Year 1: Peginterferon Beta-1a Q4W 0.288 relapses per person-years (95% CI 0.234 to 0.355) | Year 1: Peginterferon Beta-1a Q2W 0.256 relapses per person-years (95% CI 0.206 to 0.318) vs Year 1: Placebo 0.397 relapses per person-years (95% CI 0.328 to 0.481) (met)
Result source: NCT00906399
Rebif (interferon beta 1a)
Marketed by Merck KGaA and partners
NCT00110396 · Phase 3 · completed
The study was a single-group, open-label trial without randomization or a placebo or active comparator. Its primary endpoint was a laboratory antibody measure rather than a clinical outcome; 45 of 259 assessed participants were neutralising-antibody positive at week 96, but the design did not provide a controlled comparison.
Reported efficacy
Number of Participants Who Were Neutralising Antibody (NAb) Positive at the Week 96 Visit. (96 weeks): Number of Participants Who Were Neutralising Antibody (NAb) Positive at the Week 96 Visit. (96 weeks): Rebif New Formulation (RNF) Cohort 45 participants (not_applicable)
Result source: NCT00110396
Results for Multiple Sclerosis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | peginterferon beta-1a | Rebif (interferon beta 1a) |
|---|---|---|
| Annualised relapse rate | 0.3 vs 0.4−0.1 vs placeboNCT009063992 other results
| —Not posted · NCT00735007 |
| Free of 3-month confirmed disability progression (%) | —Trial running · NCT03958877 | —Not posted · NCT00735007 |
| New or enlarging T2 lesions | 7.9 vs 10.9−3 vs placeboNCT009063991 other result
| —Not posted · NCT00735007 |
Annualised relapse rate
- peginterferon beta-1a
- 0.3 vs 0.4−0.1 vs placeboNCT00906399
2 other results
- 0.3 vs 0.4 NCT00906399
- 0 vs 0.5 NCT03870763
- Rebif (interferon beta 1a)
- —Not posted · NCT00735007
Free of 3-month confirmed disability progression (%)
- peginterferon beta-1a
- —Trial running · NCT03958877
- Rebif (interferon beta 1a)
- —Not posted · NCT00735007
New or enlarging T2 lesions
- peginterferon beta-1a
- 7.9 vs 10.9−3 vs placeboNCT00906399
1 other result
- 3.6 vs 10.9 NCT00906399
- Rebif (interferon beta 1a)
- —Not posted · NCT00735007
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
1 other shared endpoint and safety
Coverage. peginterferon beta-1a: 5 of 5 rows · Rebif (interferon beta 1a): 5 of 5 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | peginterferon beta-1a | Rebif (interferon beta 1a) |
|---|---|---|
| Time to First Relapse time to event · months | NA vs 5.47 placebo months @ 96wk125 µga,b,c,d NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 | 6.34 vs 4.06 Rebif months @ 52wk*a,b,c,d NCT02727907 · Phase 2/3 · registry result, not featured evidence · converted to months from 193 days as posted |
| Dropout rate | 14.8%every 2 weekse NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 9 more results12.6%every 4 weeks NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —every 2 weeks NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —every 4 weeks NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 50%125 µg NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 18.4%BIIB017 Plus Current FLS Therapy NCT01939002 · Phase 3 · combination 18.4%BIIB017 Plus Naproxen NCT01939002 · Phase 3 · combination 22.3%Q2W NCT01332019 · Phase 3 · monotherapy 21.3%Q4W NCT01332019 · Phase 3 · monotherapy 14%125 μg NCT02587065 · Phase 4 · registry result, not featured evidence | 13.8%e NCT00110396 · Phase 3 · Multiple Sclerosis · phase 3 show 5 more results—Non-Titrated NCT00472797 · Phase 3 · registry result, not featured evidence —Titrated NCT00472797 · Phase 3 · registry result, not featured evidence 13.8% NCT00428584 · Phase 3 · registry result, not featured evidence 24.5% NCT02727907 · Phase 2/3 · registry result, not featured evidence 4.4% NCT01071083 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | 4.7%every 2 weekse NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 9 more results4.4%every 4 weeks NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —every 2 weeks NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —every 4 weeks NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 —125 µg NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 12.6%BIIB017 Plus Current FLS Therapy NCT01939002 · Phase 3 · combination 13.3%BIIB017 Plus Naproxen NCT01939002 · Phase 3 · combination 4%Q2W NCT01332019 · Phase 3 · monotherapy 2.5%Q4W NCT01332019 · Phase 3 · monotherapy 7.3%125 μg NCT02587065 · Phase 4 · registry result, not featured evidence | 5.8%e NCT00110396 · Phase 3 · Multiple Sclerosis · phase 3 show 5 more results—Non-Titrated NCT00472797 · Phase 3 · registry result, not featured evidence —Titrated NCT00472797 · Phase 3 · registry result, not featured evidence — NCT00428584 · Phase 3 · registry result, not featured evidence — NCT02727907 · Phase 2/3 · registry result, not featured evidence 0% NCT01071083 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 10.7%every 2 weekse NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 9 more results14%every 4 weeks NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 8.9%every 2 weeks NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 15.3%every 4 weeks NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 0%125 µg NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 3.9%BIIB017 Plus Current FLS Therapy NCT01939002 · Phase 3 · combination 6.1%BIIB017 Plus Naproxen NCT01939002 · Phase 3 · combination 16.6%Q2W NCT01332019 · Phase 3 · monotherapy 21.6%Q4W NCT01332019 · Phase 3 · monotherapy 0%125 μg NCT02587065 · Phase 4 · registry result, not featured evidence | 5.8%e NCT00110396 · Phase 3 · Multiple Sclerosis · phase 3 show 5 more results8.5%Non-Titrated NCT00472797 · Phase 3 · registry result, not featured evidence 5.3%Titrated NCT00472797 · Phase 3 · registry result, not featured evidence 6.2% NCT00428584 · Phase 3 · registry result, not featured evidence 0% NCT02727907 · Phase 2/3 · registry result, not featured evidence — NCT01071083 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | every 2 weekse injection site erythema 61.4% (placebo 6.6%) influenza like illness 46.4% (placebo 12.6%) pyrexia 44.2% (placebo 15%) NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 show 9 more resultsevery 4 weeks injection site erythema 56.4% (placebo 6.6%) influenza like illness 46.8% (placebo 12.6%) pyrexia 43.6% (placebo 15%) NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 every 2 weeks injection site erythema 48.4% (placebo 6.6%) influenza like illness 43.8% (placebo 12.6%) pyrexia 31.1% (placebo 15%) NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 every 4 weeks injection site erythema 48.1% (placebo 6.6%) influenza like illness 45.3% (placebo 12.6%) pyrexia 31.4% (placebo 15%) NCT00906399 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 125 µg headache 66.7% (placebo 33.3%) abdominal pain 33.3% (placebo 0%) anxiety 16.7% (placebo 0%) NCT03870763 · Phase 3 · monotherapy · Multiple Sclerosis · phase 3 injection site erythema 44.7% injection site reaction 22.3% injection site pruritus 11.7% NCT01939002 · Phase 3 · combination injection site erythema 34.7% injection site reaction 21.4% influenza like illness 13.3% NCT01939002 · Phase 3 · combination Q2W influenza like illness 42.8% injection site erythema 41% headache 29.4% NCT01332019 · Phase 3 · monotherapy Q4W influenza like illness 44.2% injection site erythema 42% multiple sclerosis relapse 29.3% NCT01332019 · Phase 3 · monotherapy 125 μg influenza like illness 14.5% injection site reactions 5.2% pyrexia 5.2% NCT02587065 · Phase 4 · registry result, not featured evidence | e influenza like illness 67.7% headache 37.7% injection site erythema 24.2% NCT00110396 · Phase 3 · Multiple Sclerosis · phase 3 show 5 more resultsheadache 24.8% pain 14.2% influenza-like illness 8% NCT00472797 · Phase 3 · registry result, not featured evidence general disorders and administration site condition 67.7% infections and infestations 58.5% nervous system disorders 44.6% NCT00428584 · Phase 3 · registry result, not featured evidence flu-like syndrom 28.3% local reaction 28.3% neutropenia 20.8% NCT02727907 · Phase 2/3 · registry result, not featured evidence nasopharyngitis 24.4% (placebo 11.9%) headache 17.8% (placebo 7.1%) dizziness 6.7% (placebo 0%) NCT01071083 · Phase 2 · registry result, not featured evidence |
Notes
- aTrial phases differ: Phase 3 versus Phase 2/3.
- bPopulation comparability has not been reviewed for both studies.
- cTreatment context has not been resolved for both arms.
- dAssessment timepoints differ: 96 weeks versus 52 weeks.
- ePopulation comparability has not been reviewed for 5 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
peginterferon beta-1a
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 3 more results
show 3 more results
show 3 more results
show 1 more result
+ 60 further endpoints in the CSV export.
Rebif (interferon beta 1a)
show 1 more result
show 2 more results
show 1 more result
show 1 more result
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: peginterferon beta-1a's landscape · Rebif (interferon beta 1a)'s landscape